Calciotropic and phosphaturic hormones in heart failure

Nutr Metab Cardiovasc Dis. 2016 Nov;26(11):971-979. doi: 10.1016/j.numecd.2016.06.007. Epub 2016 Jun 28.

Abstract

Aims: Despite adherence to evidence-based guidelines, heart failure [HF] still results in 5-year mortality rates of 50%, indicating a need to implement additional preventive/intervention strategies. This review summarizes data on alterations in the calciotropic and phosphaturic hormones 1,25-dihydroxyvitamin D [1,25(OH)2D] and fibroblast growth factors-23 [FGF-23] in HF and discusses non-pharmacological measures for targeting these hormones.

Data synthesis: The role of 1,25(OH)2D in the regulation of calcium and phosphate homeostasis is central. 1,25(OH)2D also plays a pivotal role in cardiac function, but is downregulated by FGF-23. There is accumulating evidence from epidemiological data that HF is associated with decreased circulating 1,25(OH)2D and elevated FGF-23 levels. In patients with failing hearts, very low 1,25(OH)2D and extremely high FGF-23 levels have been reported. Experimental data support the assumption that vitamin D deficiency and high serum phosphate/FGF-23 levels increase the risk of HF. This review provides a hypothesis of how vitamin D deficiency, high calcium/phosphorus intake, physical inactivity, and age-related renal impairment may all contribute to HF by adversely affecting calcium- and phosphate-regulating hormones. Several case series in infants and a meta-analysis of randomized controlled trials in adults have already reported successful treatment of or a significant risk reduction in HF by vitamin D supplements. The association of calcium/phosphorus intake, physical activity, or renal function with calciotropic/phosphaturic hormones and HF is however less well documented.

Conclusions: More attention should be paid in future to the association of circulating 1,25(OH)2D and FGF-23 levels with HF and to (non-pharmacological) measures for targeting these calciotropic/phosphaturic hormones.

Keywords: 1,25-dihydroxyvitamin D; Calcium; Fibroblast growth factor-23; Heart failure; Parathyroid hormone; Phosphate; Phosphorus; Vitamin D.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Animals
  • Biomarkers / blood
  • Calcium, Dietary / adverse effects
  • Dietary Supplements
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood*
  • Heart Failure / blood*
  • Heart Failure / diagnosis
  • Heart Failure / epidemiology
  • Heart Failure / prevention & control
  • Humans
  • Kidney Diseases / epidemiology
  • Male
  • Phosphorus, Dietary / adverse effects
  • Risk Factors
  • Sedentary Behavior
  • Treatment Outcome
  • Vitamin D / analogs & derivatives*
  • Vitamin D / blood
  • Vitamin D / therapeutic use
  • Vitamin D Deficiency / blood*
  • Vitamin D Deficiency / diagnosis
  • Vitamin D Deficiency / drug therapy
  • Vitamin D Deficiency / epidemiology

Substances

  • Biomarkers
  • Calcium, Dietary
  • FGF23 protein, human
  • Phosphorus, Dietary
  • Vitamin D
  • Fibroblast Growth Factors
  • 1,25-dihydroxyvitamin D
  • Fibroblast Growth Factor-23